Epidermal growth factor receptor inhibitors: a novel anticancer therapy.
Donegan
Sarah E
SE
Investigational Drug Service, Boston Medical Center, Boston, Massachusetts, USA.
Naples
Karen M
KM
D000911:Antibodies, Monoclonal; D016588:Anticarcinogenic Agents; D066246:ErbB Receptors / Q000187:drug effects*; D006801:Humans; D020794:Receptor Protein-Tyrosine Kinases / Q000187:drug effects
D000911:Antibodies, Monoclonal; D016588:Anticarcinogenic Agents; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases